Teva Pharma (TEVA) Reports In-Line Q4 EPS

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.31, in-line with the analyst estimate of $1.31. Revenue for the quarter came in at $5.17 billion versus the consensus estimate of $5.17 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• SanDisk upgraded at JPMorgan after investor day; shares climb